Cyclosporine and Prognosis in Acute Myocardial Infarction (MI) Patients (CIRCUS)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Hospices Civils de Lyon
ClinicalTrials.gov Identifier:
NCT01502774
First received: December 28, 2011
Last updated: April 2, 2014
Last verified: March 2014

December 28, 2011
April 2, 2014
April 2011
February 2017   (final data collection date for primary outcome measure)
Combined incidence of [total mortality; hospitalization for heart failure; LV remodeling (increase of LV end-diastolic volume > 15%)] [ Time Frame: one year post-AMI ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01502774 on ClinicalTrials.gov Archive Site
  • total mortality [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
  • cardiovascular death [ Time Frame: at 3 years ] [ Designated as safety issue: No ]
  • heart failure [ Time Frame: 3 years after acute MI ] [ Designated as safety issue: No ]
    in-hospital worsening of heart failure after reperfusion, or re-hospitalization for: 1) worsening of a heart failure existing at admission, 2) appearance of "new" heart failure
  • myocardial infarction [ Time Frame: 3 years after acute MI ] [ Designated as safety issue: No ]
  • unstable angina [ Time Frame: 3 years after acute MI ] [ Designated as safety issue: No ]
  • stroke [ Time Frame: 3 years after acute MI ] [ Designated as safety issue: No ]
  • LV remodeling [ Time Frame: 3 years after acute MI ] [ Designated as safety issue: No ]
  • Tolerance to medicinal investigational products [ Time Frame: 3 years after acute MI ] [ Designated as safety issue: Yes ]
    Adverse events
  • total mortality [ Time Frame: at 1 month and 1 year ] [ Designated as safety issue: Yes ]
  • cardiovascular death [ Time Frame: at 1 month and 1 year ] [ Designated as safety issue: No ]
  • heart failure [ Time Frame: 12 months after acute MI ] [ Designated as safety issue: No ]
    in-hospital worsening of heart failure after reperfusion, or re-hospitalization for: 1) worsening of a heart failure existing at admission, 2) appearance of "new" heart failure
  • myocardial infarction [ Time Frame: 12 months after acute MI ] [ Designated as safety issue: No ]
  • unstable angina [ Time Frame: 12 months after acute MI ] [ Designated as safety issue: No ]
  • stroke [ Time Frame: 12 months after acute MI ] [ Designated as safety issue: No ]
  • LV remodeling [ Time Frame: 12 months after acute MI ] [ Designated as safety issue: No ]
  • Tolerance to medicinal investigational products [ Time Frame: 12 months after acute MI ] [ Designated as safety issue: Yes ]
    Adverse events
Not Provided
Not Provided
 
Cyclosporine and Prognosis in Acute Myocardial Infarction (MI) Patients
Does Cyclosporine ImpRove Clinical oUtcome in ST Elevation Myocardial Infarction Patients

Infarct size is a major determinant of prognosis after Acute Myocardial Infarction (AMI). The investigators recently reported that cyclosporine A, when administered immediately prior to percutaneous coronary intervention (PCI), can significantly reduce infarct size in STEMI (ST Elevation acute Myocardial Infarction) patients. The objective of the present study is to determine whether cyclosporine can improve STEMI patient clinical outcome. Nine-hundred and seventy two patients with ST elevation MI will be entered into a multicentre, randomized, placebo-controlled, double-blinded study. They will receive one single injection of cyclosporine (or placebo) prior to reperfusion therapy by PCI. The incidence of the combined endpoint (mortality, hospitalization for heart failure, left ventricular (LV) remodeling) will be assessed at one year and three years after treatment.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
ST Elevation Acute Myocardial Infarction
  • Drug: Injection of Cyclosporin
    one single intravenous bolus injection of 2.5 mg/Kg
    Other Name: Cyclosporin (verum)
  • Drug: Placebo
    One single intravenous bolus injection of Placebo
  • Procedure: Echocardiography
    2 days, 1 year and 3 years after AMI
  • Experimental: Cyclosporin
    Injection of Cyclosporin : one single intravenous bolus injection of 2.5 mg/Kg Echocardiography
    Interventions:
    • Drug: Injection of Cyclosporin
    • Procedure: Echocardiography
  • Placebo Comparator: Control
    one single intravenous bolus injection of Placebo Echocardiography
    Interventions:
    • Drug: Placebo
    • Procedure: Echocardiography
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
972
February 2017
February 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • All patients aged over 18, having a health coverage, without any legal protection measure
  • presenting within 12 hours of the onset of chest pain,
  • who have ST segment elevation > 0.2 mV in two contiguous leads,
  • for whom the clinical decision was made to treat with percutaneous coronary intervention (PCI).
  • The culprit coronary artery has to be the LAD and has to be occluded (TIMI flow grade 0-1) at the time of admission coronary angiography.
  • Patients undergoing either primary PCI or rescue PCI are eligible for the study.

Exclusion Criteria:

  • Patients with loss of consciousness or confused
  • Patients with cardiogenic shock;
  • Patients with the left circumflex or the right coronary artery (RCA) as the culprit artery, or with evidence of coronary collaterals to the risk region;
  • Patients with an opened (TIMI > 1) LAD coronary artery at admission;
  • Patients with known hypersensitivity to cyclosporine or to egg, peanut or Soya-bean proteins,
  • known renal insufficiency (either known creatinin clearance < 30 ml/min/1.73m² or current medical care for severe renal insufficiency),
  • known liver insufficiency,
  • uncontrolled (treated or untreated) hypertension (> 180/110 mmHg);
  • Patients treated with any compound containing Hypericum perforatum (St.-John's-worth) or Stiripentol or Aliskiren or Bosentan or Rosuvastatine or with an active treatment that might modify blood concentration of Cyclosporine (diltiazem, vérapamil…);
  • Female patients currently pregnant or women of childbearing age who were not using contraception;
  • Patients with any disorder associated with immunological dysfunction more recently than 6 months prior to presentation: cancer, lymphoma, known positive serology for HIV, or hepatitis.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT01502774
2009.559
Yes
Hospices Civils de Lyon
Hospices Civils de Lyon
Not Provided
Not Provided
Hospices Civils de Lyon
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP